Adequan for Dogs: Dosage, Cost, Side Effects and What the Evidence Shows

Adequan® Canine is a prescription injection for dogs with arthritis, given into the muscle at 2 mg per pound of body weight, twice weekly for up to four weeks — a maximum of eight injections. It is the only FDA-approved polysulfated glycosaminoglycan (PSGAG) for dogs in the United States, approved for the control of signs associated with non-infectious degenerative and traumatic arthritis of canine synovial joints. It is not a painkiller, you cannot buy it without a veterinarian, and its own FDA label states that the specific mechanism of action in canine joints is not known.

That last sentence appears on the package insert and almost nowhere else on the internet. This guide sticks to what the label and the peer-reviewed literature actually say — including the parts that are less flattering than the marketing.

What is Adequan for dogs?

Adequan Canine is polysulfated glycosaminoglycan, a semi-synthetic compound extracted from bovine tracheal cartilage and chemically sulfated. It is principally chondroitin sulfate carrying three to four sulfate esters per disaccharide unit, with a molecular weight between 3,000 and 15,000 daltons. The oral chondroitin sulfate sold in supplements is a related but far less heavily sulfated molecule, and we cover chondroitin for dogs separately. It is supplied as a 100 mg/mL sterile solution in a 5 mL multiple-dose vial preserved with 0.9% benzyl alcohol.

It is approved by the FDA under NADA 141-038 and manufactured by American Regent, Inc. (Animal Health Division, Shirley, NY). Federal law restricts it to use by or on the order of a licensed veterinarian.

Two things distinguish it from the oral products in the supplement aisle. First, it bypasses the digestive tract entirely. Second, it is a regulated drug that went through an FDA approval process, which no joint supplement on the market has done. Those are real differences, and they are worth understanding before you decide anything.

Is Adequan a steroid?

No. Adequan contains no corticosteroid and no anti-inflammatory drug. It is classified as a synthetic heparinoid — structurally related to heparin — which is precisely why the label warns against using it in dogs with bleeding disorders.

How does Adequan work in dogs?

The honest answer is that nobody knows for certain. The package insert states plainly: "The specific mechanism of action of Adequan® in canine joints is not known."

What the label does offer is a proposed mechanism, and it is careful about where that evidence comes from. Experiments conducted in vitro showed PSGAG inhibiting catabolic enzymes that break down cartilage — serine proteinases, elastase, stromelysin, metalloproteases, cathepsin B1 and hyaluronidases — and enhancing some anabolic enzymes. Increased proteoglycan and hyaluronic acid synthesis was demonstrated in cultured human and rabbit chondrocytes. The detailed distribution table on the label comes from rabbits, where peak blood concentration occurred 20 to 40 minutes after intramuscular injection; the label does note that canine serum and synovial-fluid curves have been studied and appear similar to those in humans and rabbits.

Canine-specific mechanistic work exists but is more complicated than the marketing suggests. In a Cornell study of canine cartilage explants, PSGAG increased DNA content and inhibited proteoglycan degradation dose-dependently — but simultaneously reduced proteoglycan synthesis, by 19% in osteoarthritic cartilage at the lower concentration and by 55% in normal cartilage at the highest (Sevalla et al., Vet Surg 2000). The authors hedged their own conclusion with "if the results of this study extend to in vivo use."

Structural benefits have been shown in living dogs, but in a surgical model rather than in naturally occurring disease: in dogs with a transected cranial cruciate ligament — the laboratory equivalent of a torn ACL in dogs — PSGAG reduced cartilage metalloproteinase activity and improved histopathology scores (Altman et al., Arthritis Rheum 1989). Laboratory-induced arthritis in a research colony is not the same condition as the slow wear you are watching in your ten-year-old Labrador.

So: a plausible biological story, built largely on test tubes, rabbits and human cells, with the canine contribution limited mostly to distribution curves, cartilage explants and surgical models. That is not a reason to dismiss the drug. It is a reason to be skeptical of anyone who tells you confidently that Adequan rebuilds your dog's cartilage.

Adequan dosage for dogs

The approved regimen is fixed and short. There is no "loading dose" concept on the label — the eight-injection series is the protocol.

Maintenance schedules you may hear about — an injection every two to four weeks indefinitely, or repeating the series every six months — are not on the label. They are extra-label veterinary practice. Many veterinarians use them and have reasons for doing so, but that is a clinical judgment your vet makes for your individual dog, not a published protocol. Do not dose from an article, including this one.

Does Adequan need to be refrigerated?

No. The label specifies controlled room temperature, 20–25°C. Refrigerating it is unnecessary.

How successful is Adequan for dogs? What the evidence actually shows

This is the most-asked question on the search results page and the least honestly answered. Here is the entire canine clinical record, laid out.

The FDA pivotal field trial. Fifty-one dogs with radiographically confirmed joint disease in one or two joints were randomized to Adequan or saline, with blinded investigators. Twenty-four dogs (35 limbs) received the drug. Result, verbatim from the label: dogs treated with Adequan Canine showed a statistically significant improvement in range of motion and total orthopedic score over placebo-treated controls. Note what is absent — no cartilage-preservation endpoint, no radiographic-progression endpoint, and no published effect size. Anyone quoting you a success percentage is inventing it.

The trial that did not reach significance. A double-blinded, placebo-controlled study of dogs with hip dysplasia (de Haan et al., Vet Surg 1994) enrolled 111 dogs, 84 evaluable, across three PSGAG doses and a placebo. The 4.4 mg/kg group improved most and placebo least — but in the authors' own words, "the differences in clinical improvement between the four treatment groups were not statistically significant." This is a negative trial on its primary comparison, and it is almost never mentioned.

The study with no placebo group — and an interesting wrinkle. Fujiki et al. (Am J Vet Res 2007) gave PSGAG to 16 osteoarthritic dogs without an untreated arthritic comparison group. Lameness scores improved in 12 of 16, and serum cartilage oligomeric matrix protein fell in the dogs whose lameness improved. The wrinkle: the nine dogs with hindlimb lameness improved significantly, while the seven with forelimb lameness did not. A useful argument for getting a specific joint diagnosis instead of treating a generic "joint problem."

Where it ranks against everything else. A systematic review of 16 canine osteoarthritis trials using FDA evidence-based-medicine scoring (Aragon, Hofmeister & Budsberg, JAVMA 2007) concluded that a high level of comfort exists for meloxicam, and a moderate level for carprofen, etodolac, pentosan polysulphate, green-lipped mussels, P54FP, polysulfated glycosaminoglycans, and a glucosamine–chondroitin–manganese ascorbate combination. Read that list again: PSGAG sits in the same evidence tier as green-lipped mussel, and below an NSAID.

One more thing worth knowing. Objective force-plate gait analysis — the gold standard for measuring whether a dog is actually bearing more weight on a limb, as opposed to whether an owner thinks the dog looks better — has been published for fish oil omega-3s (Roush et al., JAVMA 2010) and for undenatured type II collagen (Gupta et al., 2012) in dogs. A comprehensive PubMed search returns no force-plate study of PSGAG in dogs. That absence does not mean the drug fails. It means the objective test has not been run.

How long does Adequan take to work?

Competitors give you one number. The useful version separates what is happening pharmacologically from what you might actually see across the kitchen floor.

Judge it at four weeks, not at four days. And write things down before you start: how many seconds it takes your dog to stand up from lying down, whether they take the stairs in one go, how far into a walk they start lagging. Memory is a terrible instrument for measuring slow change, and the caregiver placebo effect is large and well documented — in the placebo arm of an FDA-approved canine trial, owners judged their dog's lameness improved 39.7% of the time and veterinarians 44.8% of the time, while force-plate ground reaction forces stayed flat (Conzemius & Evans, JAVMA 2012).

What are the negative side effects of Adequan?

Reported honestly, because a side-effects section that reads rosier than the FDA label is not worth reading.

In the clinical trial: possible adverse reactions were reported after 2.1% of injections — transient injection-site pain, transient diarrhea, and one incident of abnormal bleeding. All were described as mild, self-limiting, and did not require interrupting therapy.

Post-approval reporting: the label lists, in decreasing order of frequency, vomiting, anorexia, depression/lethargy and diarrhea, and adds: "In some cases, death has been reported." These are voluntary reports and causality cannot be established from them, but the sentence is on the label and you deserve to know it is there.

From the 13-week toxicity study in 32 beagles: at ten times the label dose, one dog developed an injection-site hematoma severe enough to require euthanasia, alongside increased prothrombin time, reduced platelet count, and elevated ALT and cholesterol. The detail that matters most for normal use: intramuscular inflammation, hemorrhage and degeneration occurred in all three treated dose groups, dose-related in incidence and severity — including at one times the label dose.

Contraindications and cautions on the label

• Do not use in dogs with known or suspected bleeding disorders. PSGAG is a synthetic heparinoid. This is an absolute contraindication, not a caution.
• Do not use in dogs showing hypersensitivity to PSGAG.
• Safety in breeding, pregnant or lactating dogs has not been evaluated.
• Use with caution in dogs with renal or hepatic impairment.
• The indication is explicitly non-infectious arthritis. A hot, swollen, painful joint could be septic arthritis, which is an emergency and a different problem entirely.

If your dog has surgery scheduled — including a routine dental or spay — tell the veterinary team your dog is receiving or recently received PSGAG.

Can Adequan be given subcutaneously?

The label says intramuscular injection only. Subcutaneous administration is extra-label, and it is common in practice because it is easier for owners.

The only published data we could locate is an owner-perception survey of 69 dogs receiving subcutaneous PSGAG long-term (Varcoe, Tomlinson & Manfredi, JAAHA 2021). Thirteen of 69 owners — 18.8% — reported an adverse event. Most were minor: GI upset, loose stool, injection-site pain, fear of the needle. One was severe: thrombocytopenia with bruising, which resolved when the drug was stopped. No canine study of subcutaneous bioavailability was found, so the frequently repeated claim that "it doesn't absorb as well subcutaneously" appears to be assertion rather than measurement.

Worth keeping the routes straight: Adequan goes into muscle or under the skin, never into the joint itself. If your veterinarian has raised putting something directly into an arthritic joint — hyaluronic acid, a corticosteroid, platelet-rich plasma or a stem-cell preparation — those belong to a different category, and our guide to joint injections for dogs covers how they compare.

This is a decision for your veterinarian, who is legally permitted to prescribe extra-label and is the only person who can weigh it for your dog.

Can I buy Adequan without a vet prescription?

No. Federal law restricts this drug to use by or on the order of a licensed veterinarian. The FDA trial required radiographic confirmation of joint disease as an entry criterion, which is a reasonable indication of the level of workup involved. There is no legitimate route around the prescription, and equine PSGAG products are not interchangeable substitutes.

How much does Adequan cost for dogs?

Prices vary by pharmacy, region and vial size, and any figure printed in an article goes stale within months. What does not go stale is the arithmetic, which nobody publishes and which determines your bill.

At 1 mL per 50 lb of body weight, across eight injections, in 5 mL vials:

The volumes below are shown for cost estimation only. Your veterinarian calculates and administers the dose.

A Great Dane's loading series costs roughly five times a beagle's in drug alone, before injection fees. Two constraints tighten this further: a vial must be discarded 28 days after first puncture, and it tolerates a maximum of ten punctures. A small dog on a four-week series will not finish a vial before the clock runs out. Ask your clinic for the per-vial price and the per-injection administration fee separately — those are the two numbers that actually build your total.

Adequan vs Librela vs a daily joint supplement

These get compared constantly and they are not the same category of thing. The comparison below is deliberately about route, regulatory status and evidence — not about milligrams, because comparing an injectable drug to an oral supplement by milligram is meaningless.

There has never been a published head-to-head trial of Adequan against any oral joint supplement. Anyone claiming a supplement matches, replaces or outperforms a prescription injection is making it up. These are different tools, and for most dogs the realistic question is not which one wins but what the whole plan looks like.

If the injection your veterinarian is actually proposing is the monthly anti-NGF one rather than the PSGAG series, the detail sits in our separate guide to Librela for dogs, including the 2025 US label update.

Where a daily joint supplement legitimately fits

Two moments send owners looking: the vet quotes the cost of a series and it is out of reach, or the eight injections finish and the owner asks what happens now. A daily oral supplement belongs in that conversation as one component of a veterinarian-directed plan — never as a substitute for one.

If you are choosing one, the evidence tiers are clearer than the marketing suggests. The 2022 systematic review and meta-analysis of 72 trials in canine and feline osteoarthritis (Barbeau-Grégoire et al., Int J Mol Sci) ranked ingredient categories by measured efficacy. Omega-3-based nutraceuticals — the category in which the authors place green-lipped mussel for dogs — scored highest of any category, a ranking the authors themselves note did not reach statistical significance, with a large effect size versus controls (Cohen's d = 1.19). Collagen-based products scored weakly. And the review's conclusion on glucosamine chondroitin for dogs was blunt: a very marked non-effect, with 88.9% of trials showing no effect, leading the authors to recommend those products no longer be recommended for pain management. (The same author group discloses extensive pet-industry funding, which is worth knowing in either direction.)

That finding is inconvenient for most of the joint aisle, because most of the joint aisle is built on glucosamine and chondroitin. It is the reason our hip and joint chews for dogs are formulated with 18 actives rather than two: green-lipped mussel and omega-3s from the category the meta-analysis ranked highest, undenatured type II collagen (the form studied at 10 mg/day with force-plate confirmation in Gupta et al. 2012), plus hyaluronic acid, eggshell membrane, MSM and botanical antioxidants. Glucosamine and chondroitin are in there, but they are the floor of the formula rather than the whole of it — which is the substantive difference from the two-ingredient chews most brands sell, including those covered in our Cosequin for dogs review. Dosing is by weight: one chew up to 25 lb, two for 26–75 lb, three above that.

For a wider comparison of formats and formulas, see our guide to the best joint supplements for dogs, the best joint supplement for senior dogs, or browse the full range of dog joint and hip supplements.

If the oral option you are weighing is Nutramax's step-up formula rather than a prescription injection, its tolerance profile is worth reading first — see dasuquin for dogs side effects.

The interventions nobody on this topic mentions

Every competing article on Adequan treats arthritis as a drug-versus-drug decision. The three interventions with the strongest support in canine osteoarthritis management are free and entirely under your control:

• Body condition. Excess weight increases joint load on every step a dog takes. Nothing in a syringe or a jar competes with getting a dog to a lean body condition score.
• Controlled, consistent exercise. Short daily walks beat the weekend-warrior pattern of nothing all week and two hours on Saturday.
• Traction and access. Runners on hardwood, a ramp instead of a jump into the car, a bed that is easy to get out of. Arthritic dogs lose confidence on slick floors long before they lose the muscle.

More practical detail on this in our guide to what can I give my dog for joint pain and the wider dog joint and hip health guide.

Common mistakes owners make with Adequan

1. Judging it at week one. The trial endpoint was four weeks. Stopping at injection three because "nothing is happening" discards the part of the series where change is usually noticed.
2. Skipping the diagnosis. Fujiki's forelimb dogs did not improve. "My dog is stiff" is not a diagnosis, and the approved indication excludes infectious arthritis.
3. Not mentioning bleeding history. A dog that bruises easily, has had prolonged bleeding after a nail trim, or is a breed with von Willebrand risk needs that raised before the first injection, not after.
4. Treating it as the whole plan. The JAAHA survey found PSGAG is most commonly given alongside other medications and rehabilitation. Multimodal management is the standard of care.
5. Measuring by feeling. Without a baseline written down, you cannot tell improvement from hope.

When to call your veterinarian

A supplement is never the answer to any of these. Call your vet if you see:

• Sudden inability to bear weight on a limb, or lameness following trauma
• A joint that is hot, swollen, or painful to touch, especially with fever
• Unusual bruising, bleeding from the gums, nosebleeds, or blood in stool or vomit
• Vomiting, loss of appetite, or marked lethargy after an injection
• Swelling or a firm lump at an injection site
• Lameness that worsens despite rest, or rapid muscle loss over a limb

Not sure whether what you are seeing is arthritis at all? Start with the signs of arthritis in dogs, and read up on the range of dog arthritis medicine your veterinarian may discuss.

Frequently asked questions

How long can a dog stay on Adequan?

The FDA-approved regimen is a maximum of eight injections over four weeks. Longer-term and repeat-series use is extra-label veterinary practice rather than a labeled protocol, and the label instructs not to exceed the recommended regimen. How long your dog continues is a decision for your veterinarian based on response and health status.

What are the negative side effects of Adequan?

In the clinical trial, adverse reactions followed 2.1% of injections — injection-site pain, transient diarrhea and one bleeding incident, all mild and self-limiting. Post-approval voluntary reports list vomiting, anorexia, lethargy and diarrhea, and the label notes that in some cases death has been reported, though causality cannot be established from such reports. It is contraindicated in dogs with known or suspected bleeding disorders.

How successful is Adequan for dogs?

In the FDA field trial of 51 dogs, treated dogs showed statistically significant improvement in range of motion and total orthopedic score versus placebo. No success percentage has been published. A separate placebo-controlled trial in dogs with hip dysplasia found no statistically significant difference between groups. A 2007 systematic review placed PSGAG at a moderate level of evidentiary comfort — the same tier as green-lipped mussel, below meloxicam.

Which is better, Adequan or Librela?

They do different jobs. Adequan is a polysulfated glycosaminoglycan given intramuscularly twice weekly for four weeks and approved for control of signs of degenerative and traumatic arthritis. Librela is a monoclonal antibody against nerve growth factor, given as a monthly subcutaneous injection and approved for control of osteoarthritis pain. No published head-to-head trial compares them, and the choice depends on your dog's diagnosis, health status and tolerance — a veterinary decision.

Does Adequan rebuild cartilage in dogs?

That claim goes beyond what the label supports. The approved indication is control of signs, the label states the mechanism in canine joints is not known, and the cartilage-synthesis data come from in-vitro work and cultured human and rabbit cells. One canine explant study found PSGAG reduced proteoglycan synthesis even as it inhibited degradation.

Can I buy Adequan without a vet prescription?

No. Federal law restricts Adequan to use by or on the order of a licensed veterinarian.

Is Adequan safe for older dogs?

Age itself is not a contraindication on the label, but older dogs are more likely to have the conditions that are. The label contraindicates use in dogs with known or suspected bleeding disorders and advises caution with renal or hepatic impairment — both more common in seniors. Bloodwork before starting is a reasonable thing to ask your veterinarian about.

References

1. Adequan® Canine (polysulfated glycosaminoglycan) injection, solution — package insert. American Regent, Inc., Shirley, NY. Approved by FDA under NADA 141-038. DailyMed SPL setid 1edcf949-d6de-4921-815d-f86ccf084cae.
2. U.S. Food and Drug Administration, Center for Veterinary Medicine. Green Book: Approved Animal Drug Products — NADA 141-038, Adequan Canine.
3. de Haan JJ, Goring RL, Beale BS. Evaluation of polysulfated glycosaminoglycan for the treatment of hip dysplasia in dogs. Vet Surg. 1994;23(3):177–81. PMID: 8066981.
4. Fujiki M, Shineha J, Yamanokuchi K, Misumi K, Sakamoto H. Effects of treatment with polysulfated glycosaminoglycan on serum cartilage oligomeric matrix protein and C-reactive protein concentrations, serum matrix metalloproteinase-2 and -9 activities, and lameness in dogs with osteoarthritis. Am J Vet Res. 2007;68(8):827–33. PMID: 17669022.
5. Aragon CL, Hofmeister EH, Budsberg SC. Systematic review of clinical trials of treatments for osteoarthritis in dogs. J Am Vet Med Assoc. 2007;230(4):514–21. PMID: 17302547.
6. Sevalla K, Todhunter RJ, Vernier-Singer M, Budsberg SC. Effect of polysulfated glycosaminoglycan on DNA content and proteoglycan metabolism in normal and osteoarthritic canine articular cartilage explants. Vet Surg. 2000;29(5):407–14. PMID: 10999454.
7. Altman RD, Dean DD, Muniz OE, Howell DS. Therapeutic treatment of canine osteoarthritis with glycosaminoglycan polysulfuric acid ester. Arthritis Rheum. 1989;32(10):1300–7. PMID: 2803328.
8. Varcoe G, Tomlinson J, Manfredi J. Owner perceptions of long-term systemic use of subcutaneous administration of polysulfated glycosaminoglycan. J Am Anim Hosp Assoc. 2021;57(5):205–211. PMID: 34496011.
9. Conzemius MG, Evans RB. Caregiver placebo effect for dogs with lameness from osteoarthritis. J Am Vet Med Assoc. 2012;241(10):1314–9. PMID: 23113523.
10. Barbeau-Grégoire M, Otis C, Cournoyer A, Moreau M, Lussier B, Troncy E. A 2022 systematic review and meta-analysis of enriched therapeutic diets and nutraceuticals in canine and feline osteoarthritis. Int J Mol Sci. 2022;23(18):10384. PMID: 36142319.
11. Gupta RC, Canerdy TD, Lindley J, et al. Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. J Anim Physiol Anim Nutr. 2012;96(5):770–7. PMID: 21623931.
12. Roush JK, Cross AR, Renberg WC, et al. Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs with osteoarthritis. J Am Vet Med Assoc. 2010;236(1):67–73. PMID: 20043801.

Veterinary disclaimer. This article is educational and is not veterinary advice, a diagnosis, or a treatment plan. Adequan® is a registered trademark of American Regent, Inc.; Librela® is a registered trademark of Zoetis; Cosequin® and Dasuquin® are registered trademarks of Nutramax Laboratories. Pure Majesty Pets is not affiliated with, endorsed by, or sponsored by any of these companies. Label information is reported here as published and is not dosing guidance — only your veterinarian can prescribe, dose or administer a prescription medication for your dog. Pure Majesty Pets supplements are nutritional products intended to support normal joint function; they are not drugs, they are not intended to diagnose, treat, cure or prevent any disease, and they have not been evaluated by the FDA or Health Canada. Always consult your veterinarian before starting, stopping or changing anything in your dog's health plan.